ClinicalTrials.gg
CompletedNCT00034801Updated Jul 19, 2006

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

A Phase 4 interventional study of olanzapine and ziprasidone in Depression, Schizophrenia and Schizoaffective Disorder, sponsored by Eli Lilly and Company. Completed at 30 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2006-07-19.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Depression by Eli Lilly and Company — 2 open to participants now, 2 under way, 2 of them phase 3. Depression · Eli Lilly and Company.

Enrollment
9th of 15
378 · median 480
Started
2001
the only one that year
Phase 4
7 of 17
none open now
Registered
1st of 17
by date

Among the 17 studies in Depression by Eli Lilly and Company, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2001, is one of 7 in phase 4, and was the 1st registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,728 are open to participants now.

Browse Depression studies →

Open to participants now

2 of the 17 studies in Depression by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,090 Depression studies recruiting now, 470 (43%) set no upper age limit and 520 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depression by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a research study comparing the safety and efficacy of two active study medications

03

Conditions studied

  • Depression
  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Depression
  • Comorbid Depression
  • Schizophrenia
  • Schizoaffective Disorder
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 18-60 years of age
  • Female subjects of must be using a medically accepted means of
  • Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
  • Subjects must be considered reliable

Exclusion criteria

Exclusion Criteria:

  • Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry
  • Female subjects who are either pregnant or nursing
  • Uncorrected hypothyroidism or hyperthyroidism
  • Narrow-angle glaucoma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
378 participants

Interventions

06

Study locations

30 sites
  • Tuscaloosa, Alabama, United States
  • Little Rock, Arkansas, United States
  • Anaheim, California, United States
  • Chula Vista, California, United States
  • Lafayette, California, United States
  • Long Beach, California, United States
  • Orange, California, United States
  • Poway, California, United States
  • Rosemeade, California, United States
  • San Diego, California, United States
  • Denver, Colorado, United States
  • New Britain, Connecticut, United States
  • Winter Park, Florida, United States
  • Augusta, Georgia, United States
  • Prairie Village, Kansas, United States
  • Gaithersburg, Maryland, United States
  • Mt Pleasant, Michigan, United States
  • St Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Clementon, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Staten Island, New York, United States
  • Charlotte, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Sioux Falls, South Dakota, United States
  • Austin, Texas, United States
  • El Paso, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2001 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2002
First posted
May 3, 2002
Start
Sep 2001
Completion
Mar 2003
Last update
Jul 19, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 19, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00034801
First posted
May 3, 2002
Start date
Sep 2001
Completion
Mar 2003
Last update
Jul 19, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion